Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IGUS: IVIG in Severe Refractory Solar Urticaria
NCT01360658Phase 2Completed
- Sponsor
- CHU de Besançon
- Start
- Jun 2011
- Primary completion
- Jun 2013
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Human normal immunoglobulin G in solar urticaria (SU), sponsored by CHU de Besançon. Primary endpoint: Percentage of patients obtaining a 10 fold increase of pretherapeutic minimal urticarial dose at 3 months. Started Jun 2011; status: completed.
02
Drugs
Human normal immunoglobulin G
03
Conditions
solar urticaria (SU)
Beyond the preview
Go deeper on NCT01360658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01360658.